Edition:
United States

Apricus Biosciences Inc (APRI.PH)

APRI.PH on Philadelphia Stock Exchange

1.28USD
1 Dec 2016
Change (% chg)

-- (--)
Prev Close
$1.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
147
52-wk High
$15.40
52-wk Low
$1.28

Select another date:

Fri, Nov 18 2016

BRIEF-Apricus intends to re-submit Vitaros NDA as soon as possible in 2017

* Received feedback in response to its previously announced Type B meeting request to U.S. Food and Drug Administration

BRIEF-Apricus Biosciences posts Q3 loss per share $0.19

* Apricus Biosciences provides corporate update and third quarter financial results

BRIEF-Apricus Biosciences announces 1-for-10 reverse stock split

* Apricus Biosciences Inc - reverse stock split will be effective at 5:00 p.m. Pacific time on October 21, 2016 Source text for Eikon: Further company coverage: ;))

BRIEF-Anson Funds Management LP reports a passive stake of 7 percent in Apricus Biosciences

* Anson Funds Management LP reports a passive stake of percent in Apricus Biosciences Inc as of September 28, 2016 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Apricus Biosciences and certain investors mutually agreed to terminate certain securities purchase agreement

* On Sept 27, co and certain investors mutually agreed to terminate certain securities purchase agreement, dated Sept 22

BRIEF-Apricus Biosciences to issue about 13.1 mln shares at $0.35 per share

* Apricus Biosciences announces $4.6 million registered direct offering

BRIEF-Apricus biosciences announces completion of transfer of marketing authorizations

* Apricus Biosciences announces completion of transfer of marketing authorizations for Vitaros in Finland and Denmark to Ferring Pharmaceuticals

BRIEF-Apricus Biosciences announces approval of Vitaros for the treatment of Erectile Dysfunction in Argentina

* Apricus Biosciences announces approval of Vitaros for the treatment of erectile dysfunction in Argentina Source text for Eikon: Further company coverage:

BRIEF-Apricus Biosciences announces launch of novel topical treatment

* Apricus Biosciences announces the launch of its novel topical treatment for erectile dysfunction in Portugal, Ireland and Poland by Recordati Source text for Eikon: Further company coverage:

BRIEF-Apricus Biosciences says gets $4.5 mln in upfront payments from Ferring

* Company's partner in United Kingdom, has received United Kingdom marketing authorization for Vitaros

Select another date: